Literature DB >> 9607019

Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography.

S P Richieri1, R Bartholomew, R C Aloia, J Savary, R Gore, J Holt, F Ferre, R Musil, H R Tian, R Trauger, P Lowry, F Jensen, D J Carlo, R Z Maigetter, C P Prior.   

Abstract

This report characterizes inactivated, gp120 depleted, HIV-1 particles purified by an anion exchange chromatography production process. This antigen formulated with incomplete Freund's adjuvant constitutes Remune, which is being evaluated in a phase III clinical endpoint trial to determine the effect of this immune-based therapy on clinical progression of HIV-1 seropositive patients. Multiple production lots of the inactivated HIV-1 antigen strain HZ321, isolated by anion exchange chromatography, exhibit purity of > 95% by gel filtration. These findings are corroborated by thin section electron microscopy showing a homogenous field of intact particles. Analyses of the purified virus particles for protein, lipid, carbohydrate and RNA show structural retention of the envelope proteins, lipid bilayer and core components after large scale processing. The qualitative identification of at least 85% of total HIV-1 protein is determined by ELISA, Western blot, HPLC and amino acid sequencing analyses. Quantitative values are assigned to 50% of these proteins. The data confirm the presence of virally encoded proteins p6, p7, pI15, p17, p24, p32, pI39Gag, gp41, pp55Gag, p66/51, Vpr, Vif and Nef. Excellent consistency between production lots and equivalency to HIV-1 preparations purified by sucrose density gradient sedimentation has been established for protein and lipid composition, and overall purity. These findings further establish that non-viral encoded proteins and lipids are integral structural components of the intact virion and are not contaminants unique to a particular isolation method. The data confirm the presence of multicomponent antigens in the viral particles for stimulating a broad HIV-1 specific immune response. Finally, the work demonstrates that the two inactivation procedures (beta-propiolactone and gamma irradiation), which achieve efficient viral inactivation meeting US FDA guidelines, do not damage the protein antigens of the viral particles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607019     DOI: 10.1016/s0264-410x(97)00196-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

Review 2.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

3.  CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.

Authors:  Janina Q Jiang; Amy Patrick; Ronald B Moss; Kenneth L Rosenthal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).

Authors:  R B Moss; W Giermakowska; M R Wallace; J Savary; F Jensen; D J Carlo
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

6.  Microfluidic devices with templated regular macroporous structures for HIV viral capture.

Authors:  Krissada Surawathanawises; Kathryn Kundrod; Xuanhong Cheng
Journal:  Analyst       Date:  2016-03-07       Impact factor: 4.616

7.  Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells.

Authors:  S Mediouni; J A Jablonski; S Tsuda; A Barsamian; C Kessing; A Richard; A Biswas; F Toledo; V M Andrade; Y Even; M Stevenson; T Tellinghuisen; H Choe; M Cameron; T D Bannister; S T Valente
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

8.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.

Authors:  Erin M Scherer; Daniel P Leaman; Michael B Zwick; Andrew J McMichael; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

9.  Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.

Authors:  M Dettenhofer; X F Yu
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 10.  Molecular mechanisms of HIV-1 associated neurodegeneration.

Authors:  Hakan Ozdener
Journal:  J Biosci       Date:  2005-06       Impact factor: 2.795

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.